Vanda Salutari

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 386 citations

Advanced Ovarian Cancer, Medicine, Metronomic Therapy +7

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina et al. · Journal of Clinical Oncology · 2011 · 212 citations · Full text

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Sandro Pignata, Domenica Lorusso, Giovanni Scambia et al. · The Lancet Oncology · 2015 · 170 citations · Full text

Mito 11, Medicine, Metronomic Therapy +8

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 144 citations

Carboplatin-based Doublet, Medicine, Metronomic Therapy +7

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Michael Friedländer, Val Gebski, Emma Gibbs et al. · The Lancet Oncology · 2018 · 135 citations · Full text

Olaparib Maintenance, Health-related Quality, Medicine +9